Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Unipolar depression

Unipolar depression

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Unipolar depression

17 trials tracked for Unipolar depression: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 275 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 4 Phase 1 1 Other / NA 7
  1. Phase 3 ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) Completed · 275 cited
  2. Phase 4 A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise Completed · 45 cited
  3. Phase 4 Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression Completed · 42 cited
  4. Phase 4 The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Completed · 21 cited
  5. Phase 3 The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression Completed
  6. Phase 2 Repeated Neurocognitive Measurements in Depressed Patients Completed
Show 11 more trials
  1. Phase 2 Ketamine + Mindfulness for Depression Completed
  2. Phase 2 Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence Completed
  3. Phase 2 Pramipexole to Target "Anhedonic Depression" Completed
  4. Phase 1 Ketamine as an Adjunctive Therapy for Major Depression Completed
  5. N/A Treating Major Depression With Yoga: A Prospective, Randomized Controlled Pilot Trial Completed
  6. N/A PET and MRI Brain Imaging of Bipolar Disorder Completed
  7. N/A Novel Neural Circuit Biomarkers of Major Depression Response to CCBT Completed
  8. N/A SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project Completed
  9. N/A Tracking Depression Symptoms With a Health Chatbot Completed
  10. N/A Reaching and Engaging Depressed Senior Center Clients (REDS) Completed
  11. N/A Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Unipolar depression: what the trials found

Ketamine and its variants have been evaluated across multiple trials for unipolar depression. In a Phase 3 trial, Ketamine demonstrated significant treatment responses based on the QIDS-SR-16 scale (p=<.001) 5. Other established studies included investigations into Ketamine 3, Ketamine Hydrochloride 4, Intravenous Ketamine [8, 9], and a Phase 1 study of Ketamine 11.

Pharmacological interventions include Venlafaxine XR 2 and Wellbutrin. The latter showed statistically significant improvements on the MADRS scale (p=.04), though results on the HAM-D scale did not reach statistical significance (p=0.09) 6.

Recent results — preliminary, needs further review

  • Magnetic Seizure Therapy was evaluated for outcomes in anxiety and quality of life 1.
  • Pramipexole Pill showed improvements in both DARS and MADRS scores 7.
  • Fluoxetine was assessed in a large-scale study 12.

For the clinician treating this condition

  • Ketamine shows statistically significant evidence for treatment response in unipolar depression based on QIDS-SR-16 scales 5.
  • Wellbutrin demonstrated significant improvements on the MADRS scale, though results were not statistically significant on the HAM-D scale 6.
  • Evidence suggests that several forms of Ketamine (including intravenous and hydrochloride) are established interventions in this patient population [3, 4, 8, 9, 11].

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Administrative criteria including hospitalization and treatment changes define relapse in Major Depressive Disorder
Psychiatry Guideline
Administrative criteria including hospitalization and treatment changes define relapse in Major Depressive Disorder New Criteria Help Define Relapse in Major Depressive Disorder
This guideline reviews 51 articles to establish administrative criteria for defining relapses in patients with Major Depressive Disorder. Th…
Standardizing how doctors define depression relapse can help clarify treatment paths and improve consistency in care for patients with MDD.
Frontiers Aug 18, 2026
Oral ketamine significantly reduces depression scores with a 2.38 relative risk for remission
Psychiatry Meta-analysis
Oral ketamine significantly reduces depression scores with a 2.38 relative risk for remission Oral ketamine shows promise for treating several types of depression
This meta-analysis of RCTs involving 414 patients found that oral ketamine significantly reduced depression scores compared to placebo (SMD …
Oral ketamine may help reduce symptoms and improve remission rates for people with unipolar, bipolar, and treatment-resistant depression.
Jul 1, 2026
Psychomotor retardation in depression linked to increased Parkinson's risk
Psychiatry Cohort
Psychomotor retardation in depression linked to increased Parkinson's risk Slowed movement in depression signals higher Parkinson disease risk
A retrospective cohort study of 6327 individuals with depression found that those with psychomotor retardation had a 43% higher risk of deve…
Depression with slowed movement links to future Parkinson risk, suggesting physical signs may warn of brain changes years before diagnosis.
medRxiv Apr 28, 2026